| Wang, Xiaodong |
Circular, NCT05411705: Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury |
|
|
| Recruiting | 4 | 165 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Control, No intervention | The First Affiliated Hospital of Dalian Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Anqing Municipal Hospital, Henan Cancer Hospital, Wuhan Union Hospital, China, Peking University Shougang Hospital, Chinese PLA General Hospital, Liaoning Tumor Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital, Henan Provincial People's Hospital, Shanxi Provincial Cancer Hospital, Beijing Sanhuan Cancer Hospital, Hebei Medical University Fourth Hospital, Tongji Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Bethune Charitable Foundation | Cancer Treatment Induced Thrombocytopenia | 06/24 | 08/24 | | |
TCTN, NCT02455141: Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer |
|
|
| Recruiting | 3 | 970 | RoW | Epirubicin plus Cyclophosphamide, EC, Taxanes, Taxanes plus Carboplatin | Shanghai Jiao Tong University School of Medicine | Breast Neoplasm | 12/22 | 12/23 | | |
Neo-TACE, NCT05171166: Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. |
|
|
| Recruiting | 2/3 | 156 | RoW | HAIC, TACE, FOLFOX, oxaliplatin, leucovorin, 5-fluorouracil, cTACE or DEB-TACE, EPI, Donafenib, Dona | Peking University | Hepatocellular Carcinoma | 12/26 | 12/27 | | |
NCT04217954: HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC |
|
|
| Completed | 2 | 32 | RoW | OXA, 5-FU and bevacizumab plus Toripalimab, FOLFOX | Peking University | Advanced Biliary Tract Cancer | 05/23 | 06/23 | | |
NCT04479527: Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 34 | NA | Camrelizumab, Apatinib Mesylas | Beijing Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Hepatocellular Carcinoma | 08/23 | 12/23 | | |
NCT05166239: HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT |
|
|
| Recruiting | 2 | 66 | RoW | HAIC, Lenvatinib 1, PD-1 Inhibitors, PD-1, Lenvatinib 2, PD-1 inhibitors 2 | Peking University | Hepatocellular Carcinoma, Portal Vein Thrombosis | 12/23 | 12/24 | | |
NCT05024513: Biliary Drainage Plus HAIC in Locally Advanced PCCA |
|
|
| Recruiting | 2 | 127 | RoW | oxaliplatin and 5-fluorouracil, Biliary Drainage, Best Supportive Care, External biliary drainage | Peking University | Perihilar Cholangiocarcinoma | 03/25 | 05/26 | | |
NCT06739252: Perioperative Treatment of High-risk Resectable CCA with HAIC Plus A+T: Neobrave CCA |
|
|
| Recruiting | 2 | 30 | RoW | Gemcitabine Oxaliplatin and 5FU | Peking University | Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma | 12/25 | 12/26 | | |
| Recruiting | 1 | 112 | RoW | TQB3006 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Neoplasm | 03/25 | 08/26 | | |
SALVLIV, NCT06199232: Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed from Standard Systemic Treatment |
|
|
| Recruiting | N/A | 47 | RoW | HAIC+targeted therapy+PD-1 inhibitor, HAIC+Fruquintinib/Cetuximab+Tislelizumab | Peking University | Liver Metastasis Colon Cancer, CtDNA Genotype, MSS, Failed from Standard Treatment | 01/26 | 01/27 | | |
NCT05484895: Mobile Health Intervention to Increase HIV Testing and Linkage to Care |
|
|
| Active, not recruiting | N/A | 1800 | RoW | WeTest-WeLink, Control condition | Emory University, Anhui Medical University, Rutgers University, University of Arkansas, National Institute of Mental Health (NIMH) | HIV | 01/25 | 01/25 | | |
| Recruiting | N/A | 190 | RoW | | Peking University Cancer Hospital & Institute | DMMR Cancer, MSI-H, Solid Tumor | 02/26 | 02/26 | | |
